Comparison of Fluoroscopy-only vs. Electroanatomic Mapping Strategies for Pulmonary Vein Isolation With Balloon-based Pulsed-field Ablation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-05

Study Completion Date

2026-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We designed a study to evaluate the impact of a two systematic strategies for PVI with the octaspline, balloon-based PFA (B-PFA) catheter. We hypothesized that the addition of electroanatomic guidance is non-superior to fluoroscopy-only guidance in achieving durable PVI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ganglionated Plexi Ablation Combined With Pulmonary Vein Isolation

NCT01703247

Persistent Atrial Fibrillation

COMPLETED PHASE2

Pulmonary Vein Isolation Alone or in Combination With Substrate Modulation After Electric Cardioversion Failure

NCT05264831

Persistent Atrial Fibrillation

RECRUITING NA

SVC-isolation in Redo-AF Ablation With Isolated PV

NCT07112716

Paroxysmal AF

NOT_YET_RECRUITING NA

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

NCT04428944

Atrial Fibrillation

ACTIVE_NOT_RECRUITING NA

Assessment of Pulmonary Vein Isolation Using a Balloon Catheter With Pulsed Field Energy in Atrial Fibrillation

NCT07156877

Atrial Fibrillation (AF)

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design This is a single-center, randomized clinical study enrolling consecutive paroxysmal or persistent AF patients undergoing PVI with a B-PFA catheter (ClinicalTrials.gov identifier: pending). Patients will be randomized in a 1:1 basis to a fluoroscopy-only strategy vs. a strategy based on the same fluoroscopy workflow but with the addition of electroanatomic mapping (EAM).

Procedures will be carried out under deep sedo-analgesia with propofol and fentanyl. Patients will be scheduled for systematic, invasive remapping of the left atrium (LA) and pulmonary veins (PVs) a minimum of 30 days after index ablation, regardless of recurrence status.

The study will be carried out in University Hospital 12 de Octubre, a tertiary academic hospital, and has already received approval from the corresponding Institutional Review Board (code 23/208, mod. 2).

Patient data will be handled according to the current General Data Protection Regulation 2016/679 of the European Parliament (EU-GDPR) and the Council of 27 April 2016 on Personal Data Protection as well as national and local regulations regarding patient autonomy, and rights and obligations in terms of information and clinical documentation.

After a run-in phase of 10 cases per operator, 96 patients will be consecutively enrolled during a 4-month period (Figure 1).

Randomization Patients who meet all eligibility criteria and provide informed consent will be assigned in a 1:1 ratio to one of two treatment arms: (1) PVI using fluoroscopy-only as guidance (control group) or (2) PVI guided by fluoroscopy with the addition of EAM (experimental group). Randomization will be performed electronically at each participating center via the Research Electronic Data Capture (REDCap®) platform (Vanderbilt University, Nashville, TN, USA). A computer-generated permuted block sequence, with stratification by AF presentation (paroxysmal or persistent), will be used to ensure balanced allocation.

Study population Patients ≥18 years old, diagnosed with paroxysmal or persistent AF and clinical indication to undergo PVI will be included. Exclusion criteria are prior PVI or left atrial linear ablation, severe frailty or life expectancy \<1 year, unwillingness or inability to provide informed consent, ablation at sites beyond PVI or indication for additional electrophysiological study, contraindication or intolerance to heparin, presence of left atrial thrombus, congenital heart disease, and pregnancy, ongoing or planned in the following 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

All events related to the dual primary efficacy outcomes and primary safety outcome will be reviewed by an independent committee. These physicians will be responsible for reviewing the acute and chronic (\>30 days) left atrial maps. Their role will be to determine PVI status and to define the type of adverse event according to its severity and relevance to the study. This committee will consist of three electrophysiologists who will not participate in the ablation or remapping procedures and who will be blinded to the characteristics of the index procedure.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fluoroscopy only

Fluoroscopy-only guidance throughout the procedure

Group Type ACTIVE_COMPARATOR

Pulmonary vein isolation

Intervention Type DEVICE

Pulsed field ablation for pulmonary vein isolation in atrial fibrillation ablation

Fluoroscopy and electroanatomic mapping

Both fluoroscopy and electroanatomic mapping guidance

Group Type EXPERIMENTAL

Pulmonary vein isolation

Intervention Type DEVICE

Pulsed field ablation for pulmonary vein isolation in atrial fibrillation ablation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pulmonary vein isolation

Pulsed field ablation for pulmonary vein isolation in atrial fibrillation ablation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years old
* Diagnosed with paroxysmal or persistent AF
* Clinical indication to undergo PVI

Exclusion Criteria

* Prior PVI or left atrial linear ablation
* Severe frailty or life expectancy \<1 year
* Unwillingness or inability to provide informed consent
* Ablation at sites beyond PVI or indication for additional electrophysiological study
* Contraindication or intolerance to heparin
* Presence of left atrial thrombus
* Congenital heart disease
* Pregnancy, ongoing or planned in the following 6 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No